Authors:
Venza, I
Giordano, L
Piraino, G
Medici, N
Ceci, G
Teti, D
Citation: I. Venza et al., Prostaglandin E2 signalling pathway in human T lymphocytes from healthy and conjunctiva basal cell carcinoma-bearing subjects, IMM CELL B, 79(5), 2001, pp. 482-489
Authors:
Cocconi, G
Bella, M
Lottici, R
Leonardi, F
Ceci, G
Passalacqua, R
Di Blasio, B
Bordi, C
Biscottini, B
Melpignano, M
De Biasi, D
Finardi, C
Bacchi, M
Citation: G. Cocconi et al., Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma, AM J CL ONC, 22(6), 1999, pp. 559-567
Authors:
Cocconi, G
Bisagni, G
Ceci, G
Blasio, BD
De Lisi, V
Passalacqua, R
Zadro, A
Boni, C
Morandi, P
Savoldi, L
Citation: G. Cocconi et al., Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial, BREAST CANC, 56(2), 1999, pp. 125-132
Authors:
Boni, C
Savoldi, L
Bisagni, G
Ceci, G
Crino, L
De Lisi, V
Di Costanzo, F
Lasagni, L
Manenti, AL
Moretti, G
Rondini, E
Sassi, M
Zadro, A
Citation: C. Boni et al., Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): A phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC), EUR J CANC, 34(12), 1998, pp. 1974-1976